Has Vaidehi Dedania, MD received payments from drug or device companies?

Yes. Drug and device makers reported $44,566 in general payments to Vaidehi Dedania, MD across 111 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vaidehi Dedania, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vaidehi Dedania, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vaidehi Dedania, MD

Ophthalmology · New York, NYNPI 1144510637

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $31,618 of the $44,566 with a category attached, or 70.9%. 19 manufacturers reported payments, led by AbbVie at 30.6% of the total. Reporting peaked in 2019 at $11,287 and has fallen 64.6% since, to $3,992 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$44,566in general payments, 2019–2025

Across 111 payments — averaging $401.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$14K
Astellas Pharma US Inc$8K
Alimera Sciences, Inc.$4K
Eyepoint US, Inc.$4K
Regeneron$3K
Genentech USA, Inc.$3K
plus $9K from 13 others

$197,319in research payments, 2019–2025

Across 30 payments — averaging $6577.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$197K
F. Hoffmann-la Roche AG$426

What the payments were for

Consulting fees$31,61871%
Speaking & faculty fees$5,91513%
Travel & lodging$6661%
Food & beverage$6,36814%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	29	$13,638
Astellas Pharma US Inc	3	$8,110
Alimera Sciences, Inc.	10	$4,346
Eyepoint US, Inc.	9	$3,724
Regeneron	6	$2,945
Genentech USA, Inc.	5	$2,555
Novartis	4	$2,321
ANI Pharmaceuticals, Inc.	2	$2,037
Spark Therapeutics, Inc.	3	$1,630
Apellis Pharmaceuticals, Inc.	20	$1,626
Alcon	5	$620
Regeneron Healthcare Solutions, Inc.	6	$408
Dutch Ophthalmic, USA	2	$251
Genentech, Inc.	2	$84
Johnson & Johnson Surgical Vision, Inc.	1	$81
Bausch & Lomb Americas Inc.	1	$79
Carl Zeiss Meditec, Inc.	1	$70
Bausch & Lomb, A Division Of Bausch Health US, LLC	1	$22
Tarsus Pharmaceuticals, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,566 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York →

Medicare billing

Part B allowed, 2024

$273,827

Medicare patients

349

Services billed

4,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	33	$2,114
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	31	$711
Timolol Maleate	21	$183

Paid to pharmacies, not to this prescriber.

Other ophthalmology in New York

Nathan RadcliffeNew York$2.1M
Richard SpaideNew York$1.7M
Joshua YoungNew York$814K
Joseph PanarelliNew York$541K
Eric RosenbergNew York$434K
Michael CooneyNew York$398K
David GuyerNew York$322K
Ashley BrissetteNew York$315K
Jason SlakterNew York$272K
David ChuNew York$234K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →